Welcome to our dedicated page for Maase SEC filings (Ticker: MAAS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Maase Inc. (NASDAQ: MAAS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer. Maase Inc. files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, reflecting its status as a China-based financial technology and services group with expanding interests in new energy technologies, intelligent unmanned systems, and healthcare and wellness.
Through these filings, investors can follow key corporate events and structural changes. Recent Form 6-K reports describe share transfer agreements involving Puyi Group Limited and Puyi Holdings (Hong Kong) Limited and state that, upon completion of the transaction, Maase Inc. will cease all fund product distribution operations. Other 6-K filings detail the transaction agreements and subsequent completion of acquisitions such as Carve Group Ltd and Real Prospect Limited, which give Maase Inc. ownership interests in businesses focused on wild-grown ginseng resources, bird’s nest biotechnology, new energy technologies, and intelligent unmanned car wash systems.
Filings also document capital markets activity, including a private placement of Class A ordinary shares and warrants, with explanations of the dual-class share structure and the intended use of proceeds for business plans, working capital, and other corporate purposes. Additional 6-K reports cover changes to the company’s Chinese name, approved by the board of directors, and provide context for how Maase Inc. aligns its branding with its evolving business focus.
On Stock Titan, these SEC filings are updated in step with EDGAR and paired with AI-powered summaries that highlight the main terms of each transaction, shifts in business lines, and governance changes. Users can quickly locate Maase Inc.’s current reports, understand the implications of share transfers, acquisitions, and private placements, and review how the company describes its strategic direction in its own regulatory language.
Golden Brighter Limited and its sole owner Baron Ren filed a Schedule 13D reporting that Golden Brighter received 93,049,939 Class A ordinary shares of Maase Inc. following an issuance completed on August 27, 2025 as consideration for the acquisition of Carve Group Ltd. Those shares represent 41.95% of Maase's outstanding ordinary shares but only 10.55% of aggregate voting power because Maase has a dual-class structure with Class B shares carrying 100 votes each. The shares held by Golden Brighter (and thus beneficially by Mr. Ren) are subject to a five-year lock-up for Golden Brighter and WJ Management Company Limited. The reporting persons state the stake was acquired for investment purposes and reserve the right to review or change their intentions, including possible communications with management or shareholders. The Transaction Agreement is filed as an exhibit to Maase's Form 6-K.
Maase Inc. (NASDAQ: MAAS) disclosed a Transaction Agreement (Exhibit 10.1) dated 28 July 2025 to acquire 100% of Carve Group Ltd. The purchase price is 195,894,609 Class A shares of MAAS valued at US$1.50 each, implying consideration of roughly US$293.8 million. Closing is targeted for Q3 2025 and is subject to customary conditions.
Prior to closing, the sellers will complete a reorganization that will place two operating businesses under the target: Zhongshen Resources, which controls 111 mu of ginseng-rich forest land containing 19,000+ 40-year-old wild roots, and Glyken Bird Nest Technology, a biotech producer capable of ~10 tons of bird-nest peptides per year with multiple consumer product lines. Shares issued to Golden Brighter Ltd. and WJ Management Ltd. carry a 5-year lock-up.
The board of MAAS has approved the deal. Upon completion MAAS will own the target outright, expanding into traditional Chinese medicine ingredients and bird-nest biotechnology. The all-stock structure preserves cash but will expand the share count materially.